TMED
T. Rowe Price Health Care ETF
T. Rowe Price Exchange-Traded Funds, Inc.
ETF
Expense ratio1
0.44%
Net assets2
$20.26M
Holdings2
105
Category
US Equity
Return

Investment objective & strategy

As of Feb. 25, 2026 · prospectus

Objective. The fund seeks long-term capital appreciation.

Strategy. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of health care companies. The fund defines health care companies as companies engaged in health care innovations, such as developing new and effective therapies; pharmaceuticals; biotechnology; life sciences tools and services; managed health care; and/or health care equipment, supplies, providers, services, distributors, and facilities. The fund references the MSCI GICS (Global Industry Classification Standard) Health Care sector to identify such companies. Any derivatives that provide exposure to the investment focus suggested by the funds name, or to one or more market risk factors associated with the investment focus suggested by the funds name, are counted (as applicable) toward compliance with … The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of health care companies. The fund defines health care companies as companies engaged in health care innovations, such as developing new and effective therapies; pharmaceuticals; biotechnology; life sciences tools and services; managed health care; and/or health care equipment, supplies, providers, services, distributors, and facilities. The fund references the MSCI GICS (Global Industry Classification Standard) Health Care sector to identify such companies. Any derivatives that provide exposure to the investment focus suggested by the funds name, or to one or more market risk factors associated with the investment focus suggested by the funds name, are counted (as applicable) toward compliance with the funds 80% investment policy. As a fundamental policy, the fund will concentrate (invest more than 25% of its net assets) in health care companies. The majority of the fund will be invested in equity securities, such as common stocks. While most assets are typically invested in U.S. common stocks, the fund may invest in foreign stocks in keeping with its objective. The fund uses fundamental, bottom-up analysis and may invest in companies of any market capitalization. The adviser may use both growth and value approaches in selecting investments for the fund. The fund is nondiversified, which means it may invest a greater percentage of its assets in a particular issuer than is permissible for a diversified fund.

Top holdings

As of March 31, 2026 · N-PORT
SecurityTickerValue% of fund
LILLY ELI and CO $2.93M 14.48%
UNITEDHEALTH GRP $1.33M 6.54%
THERMO FISHER SCIENTIFIC INC $930.47K 4.59%
GILEAD SCIENCES INC $839.01K 4.14%
ABBOTT LABS $792.61K 3.91%
DANAHER CORP $553.25K 2.73%
MEDTRONIC PLC $454.48K 2.24%
ALNYLAM PHARMACEUTICALS INC $417.56K 2.06%
STRYKER CORP $405.81K 2.00%
DYNE THERAPEUTICS INC $380.17K 1.88%
View all holdings →

Allocation by sector

As of March 31, 2026 · N-PORT
View portfolio breakdown →

Portfolio moves

Dec 31, 2025 → Mar 31, 2026
Opened
25
Exited
23
Increased
65
Decreased
15
Unchanged
3

How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.

View portfolio moves →

Similar funds

Funds whose portfolios most overlap this one, by weight

Advisers

As of December 31, 2025 · N-CEN
FirmRole
T. Rowe Price Associates, Inc. Adviser
T. Rowe Price Investment Management, Inc. Sub-adviser

Footnotes

  1. Expense ratio as of February 25, 2026, from the fund's prospectus.
  2. Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.

Machine-readable: JSON · Markdown. Programmatic access via the agent surface.